Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14690796 | 1.00 | DUT (0.39) | DUTLMNAMAOASLC6A2PKM | |
| SCHEMBL21400915 | 0.96 | DUT (0.40) | DUTLMNAMAOASLC6A2PKM | |
| SCHEMBL16180004 | 0.91 | LMNA (0.40) | DUTLMNAMAOASLC6A2PKM | |
| SCHEMBL2287916 | 0.91 | LMNA (0.40) | DUTLMNAMAOASLC6A2PKM | |
| SCHEMBL1712032 | 0.91 | LMNA (0.40) | DUTLMNAMAOASLC6A2PKM | |
| SCHEMBL21428625 | 0.82 | LMNA (0.49) | LMNAMAOASLC6A2PKMUSP2 | |
| SCHEMBL2288476 | 0.82 | LMNA (0.49) | LMNAMAOASLC6A2PKMUSP2 | |
| SCHEMBL20519513 | 0.82 | LMNA (0.49) | LMNAMAOASLC6A2PKMUSP2 | |
| SCHEMBL591257 | 0.75 | ALDH1A1 (0.44) | DUTALDH1A1MAPK1 | |
| SCHEMBL16878814 | 0.73 | DUT (0.36) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916573-B2 | Quinazoline-2,4-dione derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-23 | — | — | US | disclosed |
| US-20140171425-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-06-19 | — | — | US | disclosed |
| EP-2742042-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013021363-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171425-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES | NQO2, H1-3, H1-0 | DUT 836/4885LMNA 2400/4885MAOA 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.